- The companies collaborate to initiate P-I/II study assessing the combination of iTeos’ EOS100850 and Merck’s Keytruda (pembrolizumab) for patients with solid tumors. The companies plan the onset of the study in H1’20
- The focus of the study is to determine the safety and tolerability of the combination regimen in solid tumors
- EOS100850 is a non-brain penetrant A2A receptor antagonist that holds potency in the presence of elevated adenosine concentrations, measured in the tumor microenvironment and is being evaluated in P-I/Ib as monothx.
Click here to read full press release/ article | Ref: iTeos Therapeutics | Image: HBM Partners